The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Alan Kaplan; Heath Heatley; John Townend; Derek Skinner; Victoria Carter; Richard Hubbard; Tan Tze Lee; Mariko Siyue Koh; David Price

doi:10.1007/s12325-025-03175-x

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Alan Kaplan, Heath Heatley, John Townend, Derek Skinner, Victoria Carter, Richard Hubbard, Tan Tze Lee, Mariko Siyue Koh, David Price

Research output: Journal Publication › Article › peer-review

Abstract

To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

Original language	English
Article number	e30812
Pages (from-to)	2950-2956
Number of pages	7
Journal	Advances in Therapy
Volume	42
Issue number	6
DOIs	https://doi.org/10.1007/s12325-025-03175-x
Publication status	Published - Jun 2025
Externally published	Yes

Keywords

Asthma
Asthma outcomes
GLP1s
Obesity

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12325-025-03175-x

Cite this

@article{23a03d73dcaa4b709668824f3347db04,

title = "The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity",

abstract = "To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95\% CI 1.90–2.36) and OAC (OR 2.10, 95\%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.",

keywords = "Asthma, Asthma outcomes, GLP1s, Obesity",

author = "Alan Kaplan and Heath Heatley and John Townend and Derek Skinner and Victoria Carter and Richard Hubbard and Lee, \{Tan Tze\} and Koh, \{Mariko Siyue\} and David Price",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jun,

doi = "10.1007/s12325-025-03175-x",

language = "English",

volume = "42",

pages = "2950--2956",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "6",

}

TY - JOUR

T1 - The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

AU - Kaplan, Alan

AU - Heatley, Heath

AU - Townend, John

AU - Skinner, Derek

AU - Carter, Victoria

AU - Hubbard, Richard

AU - Lee, Tan Tze

AU - Koh, Mariko Siyue

AU - Price, David

N1 - Publisher Copyright: © The Author(s) 2025.

PY - 2025/6

Y1 - 2025/6

N2 - To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

AB - To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.

KW - Asthma

KW - Asthma outcomes

KW - GLP1s

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=105002171129&partnerID=8YFLogxK

U2 - 10.1007/s12325-025-03175-x

DO - 10.1007/s12325-025-03175-x

M3 - Article

C2 - 40198520

AN - SCOPUS:105002171129

SN - 0741-238X

VL - 42

SP - 2950

EP - 2956

JO - Advances in Therapy

JF - Advances in Therapy

IS - 6

M1 - e30812

ER -

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this